Highlights
The global GMP Protein (E. coli) Contract Manufacturing market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.
North American market for GMP Protein (E. coli) Contract Manufacturing is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
Asia-Pacific market for GMP Protein (E. coli) Contract Manufacturing is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
The global market for GMP Protein (E. coli) Contract Manufacturing in Biotechnology and Pharmaceutical Companies is estimated to increase from $ million in 2022 to $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
The major global companies of GMP Protein (E. coli) Contract Manufacturing include Merck, Thermo Fisher Scientific, Abcam, GenScript, Biomay, SOL GROUP, Proteintech Group, Nordmark Pharma and Sino Biological, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.
Considering the economic change due to COVID-19, Gene Therapy, which accounted for % of the global market of GMP Protein (E. coli) Contract Manufacturing in 2021, is expected to reach US$ million by 2028, growing at a revised CAGR of % from 2022 to 2028.
Report Scope
This report aims to provide a comprehensive presentation of the global market for GMP Protein (E. coli) Contract Manufacturing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding GMP Protein (E. coli) Contract Manufacturing.
The GMP Protein (E. coli) Contract Manufacturing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global GMP Protein (E. coli) Contract Manufacturing market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the GMP Protein (E. coli) Contract Manufacturing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & 麻豆原创 Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Merck
Thermo Fisher Scientific
Abcam
GenScript
Biomay
SOL GROUP
Proteintech Group
Nordmark Pharma
Sino Biological
Abnova Corporation
Eurofins Scientific
Arcline Investment Management
Abgenex
Xpress Biologics
Avid Bioservices
Bio-Techne
Northway Biotech
Aldevron
Institut M茅rieux
PerkinElmer
Creative BioMart
Profacgen
ProBioGen
Product Type Insights
Global markets are presented by GMP Protein (E. coli) Contract Manufacturing type, along with growth forecasts through 2028. Estimates on revenue are based on the price in the supply chain at which the GMP Protein (E. coli) Contract Manufacturing are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).
GMP Protein (E. coli) Contract Manufacturing segment by Type
Gene Therapy
Cell Therapy
Application Insights
This report has provided the market size (revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the GMP Protein (E. coli) Contract Manufacturing market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the GMP Protein (E. coli) Contract Manufacturing market.
GMP Protein (E. coli) Contract Manufacturing Segment by Application
Biotechnology and Pharmaceutical Companies
Academic & Research Institutes
Contract Research Organizations
Others
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the GMP Protein (E. coli) Contract Manufacturing market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GMP Protein (E. coli) Contract Manufacturing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of GMP Protein (E. coli) Contract Manufacturing and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the GMP Protein (E. coli) Contract Manufacturing industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GMP Protein (E. coli) Contract Manufacturing.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of GMP Protein (E. coli) Contract Manufacturing companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global GMP Protein (E. coli) Contract Manufacturing 麻豆原创 Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Gene Therapy
1.2.3 Cell Therapy
1.3 麻豆原创 by Application
1.3.1 Global GMP Protein (E. coli) Contract Manufacturing 麻豆原创 Share by Application: 2017 VS 2021 VS 2028
1.3.2 Biotechnology and Pharmaceutical Companies
1.3.3 Academic & Research Institutes
1.3.4 Contract Research Organizations
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global GMP Protein (E. coli) Contract Manufacturing 麻豆原创 Perspective (2017-2028)
2.2 GMP Protein (E. coli) Contract Manufacturing Growth Trends by Region
2.2.1 GMP Protein (E. coli) Contract Manufacturing 麻豆原创 Size by Region: 2017 VS 2021 VS 2028
2.2.2 GMP Protein (E. coli) Contract Manufacturing Historic 麻豆原创 Size by Region (2017-2022)
2.2.3 GMP Protein (E. coli) Contract Manufacturing Forecasted 麻豆原创 Size by Region (2023-2028)
2.3 GMP Protein (E. coli) Contract Manufacturing 麻豆原创 Dynamics
2.3.1 GMP Protein (E. coli) Contract Manufacturing Industry Trends
2.3.2 GMP Protein (E. coli) Contract Manufacturing 麻豆原创 Drivers
2.3.3 GMP Protein (E. coli) Contract Manufacturing 麻豆原创 Challenges
2.3.4 GMP Protein (E. coli) Contract Manufacturing 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top GMP Protein (E. coli) Contract Manufacturing Players by Revenue
3.1.1 Global Top GMP Protein (E. coli) Contract Manufacturing Players by Revenue (2017-2022)
3.1.2 Global GMP Protein (E. coli) Contract Manufacturing Revenue 麻豆原创 Share by Players (2017-2022)
3.2 Global GMP Protein (E. coli) Contract Manufacturing 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by GMP Protein (E. coli) Contract Manufacturing Revenue
3.4 Global GMP Protein (E. coli) Contract Manufacturing 麻豆原创 Concentration Ratio
3.4.1 Global GMP Protein (E. coli) Contract Manufacturing 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by GMP Protein (E. coli) Contract Manufacturing Revenue in 2021
3.5 GMP Protein (E. coli) Contract Manufacturing Key Players Head office and Area Served
3.6 Key Players GMP Protein (E. coli) Contract Manufacturing Product Solution and Service
3.7 Date of Enter into GMP Protein (E. coli) Contract Manufacturing 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 GMP Protein (E. coli) Contract Manufacturing Breakdown Data by Type
4.1 Global GMP Protein (E. coli) Contract Manufacturing Historic 麻豆原创 Size by Type (2017-2022)
4.2 Global GMP Protein (E. coli) Contract Manufacturing Forecasted 麻豆原创 Size by Type (2023-2028)
5 GMP Protein (E. coli) Contract Manufacturing Breakdown Data by Application
5.1 Global GMP Protein (E. coli) Contract Manufacturing Historic 麻豆原创 Size by Application (2017-2022)
5.2 Global GMP Protein (E. coli) Contract Manufacturing Forecasted 麻豆原创 Size by Application (2023-2028)
6 North America
6.1 North America GMP Protein (E. coli) Contract Manufacturing 麻豆原创 Size (2017-2028)
6.2 North America GMP Protein (E. coli) Contract Manufacturing 麻豆原创 Size by Country (2017-2022)
6.3 North America GMP Protein (E. coli) Contract Manufacturing 麻豆原创 Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe GMP Protein (E. coli) Contract Manufacturing 麻豆原创 Size (2017-2028)
7.2 Europe GMP Protein (E. coli) Contract Manufacturing 麻豆原创 Size by Country (2017-2022)
7.3 Europe GMP Protein (E. coli) Contract Manufacturing 麻豆原创 Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific GMP Protein (E. coli) Contract Manufacturing 麻豆原创 Size (2017-2028)
8.2 Asia-Pacific GMP Protein (E. coli) Contract Manufacturing 麻豆原创 Size by Country (2017-2022)
8.3 Asia-Pacific GMP Protein (E. coli) Contract Manufacturing 麻豆原创 Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America GMP Protein (E. coli) Contract Manufacturing 麻豆原创 Size (2017-2028)
9.2 Latin America GMP Protein (E. coli) Contract Manufacturing 麻豆原创 Size by Country (2017-2022)
9.3 Latin America GMP Protein (E. coli) Contract Manufacturing 麻豆原创 Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa GMP Protein (E. coli) Contract Manufacturing 麻豆原创 Size (2017-2028)
10.2 Middle East & Africa GMP Protein (E. coli) Contract Manufacturing 麻豆原创 Size by Country (2017-2022)
10.3 Middle East & Africa GMP Protein (E. coli) Contract Manufacturing 麻豆原创 Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Detail
11.1.2 Merck Business Overview
11.1.3 Merck GMP Protein (E. coli) Contract Manufacturing Introduction
11.1.4 Merck Revenue in GMP Protein (E. coli) Contract Manufacturing Business (2017-2022)
11.1.5 Merck Recent Development
11.2 Thermo Fisher Scientific
11.2.1 Thermo Fisher Scientific Company Detail
11.2.2 Thermo Fisher Scientific Business Overview
11.2.3 Thermo Fisher Scientific GMP Protein (E. coli) Contract Manufacturing Introduction
11.2.4 Thermo Fisher Scientific Revenue in GMP Protein (E. coli) Contract Manufacturing Business (2017-2022)
11.2.5 Thermo Fisher Scientific Recent Development
11.3 Abcam
11.3.1 Abcam Company Detail
11.3.2 Abcam Business Overview
11.3.3 Abcam GMP Protein (E. coli) Contract Manufacturing Introduction
11.3.4 Abcam Revenue in GMP Protein (E. coli) Contract Manufacturing Business (2017-2022)
11.3.5 Abcam Recent Development
11.4 GenScript
11.4.1 GenScript Company Detail
11.4.2 GenScript Business Overview
11.4.3 GenScript GMP Protein (E. coli) Contract Manufacturing Introduction
11.4.4 GenScript Revenue in GMP Protein (E. coli) Contract Manufacturing Business (2017-2022)
11.4.5 GenScript Recent Development
11.5 Biomay
11.5.1 Biomay Company Detail
11.5.2 Biomay Business Overview
11.5.3 Biomay GMP Protein (E. coli) Contract Manufacturing Introduction
11.5.4 Biomay Revenue in GMP Protein (E. coli) Contract Manufacturing Business (2017-2022)
11.5.5 Biomay Recent Development
11.6 SOL GROUP
11.6.1 SOL GROUP Company Detail
11.6.2 SOL GROUP Business Overview
11.6.3 SOL GROUP GMP Protein (E. coli) Contract Manufacturing Introduction
11.6.4 SOL GROUP Revenue in GMP Protein (E. coli) Contract Manufacturing Business (2017-2022)
11.6.5 SOL GROUP Recent Development
11.7 Proteintech Group
11.7.1 Proteintech Group Company Detail
11.7.2 Proteintech Group Business Overview
11.7.3 Proteintech Group GMP Protein (E. coli) Contract Manufacturing Introduction
11.7.4 Proteintech Group Revenue in GMP Protein (E. coli) Contract Manufacturing Business (2017-2022)
11.7.5 Proteintech Group Recent Development
11.8 Nordmark Pharma
11.8.1 Nordmark Pharma Company Detail
11.8.2 Nordmark Pharma Business Overview
11.8.3 Nordmark Pharma GMP Protein (E. coli) Contract Manufacturing Introduction
11.8.4 Nordmark Pharma Revenue in GMP Protein (E. coli) Contract Manufacturing Business (2017-2022)
11.8.5 Nordmark Pharma Recent Development
11.9 Sino Biological
11.9.1 Sino Biological Company Detail
11.9.2 Sino Biological Business Overview
11.9.3 Sino Biological GMP Protein (E. coli) Contract Manufacturing Introduction
11.9.4 Sino Biological Revenue in GMP Protein (E. coli) Contract Manufacturing Business (2017-2022)
11.9.5 Sino Biological Recent Development
11.10 Abnova Corporation
11.10.1 Abnova Corporation Company Detail
11.10.2 Abnova Corporation Business Overview
11.10.3 Abnova Corporation GMP Protein (E. coli) Contract Manufacturing Introduction
11.10.4 Abnova Corporation Revenue in GMP Protein (E. coli) Contract Manufacturing Business (2017-2022)
11.10.5 Abnova Corporation Recent Development
11.11 Eurofins Scientific
11.11.1 Eurofins Scientific Company Detail
11.11.2 Eurofins Scientific Business Overview
11.11.3 Eurofins Scientific GMP Protein (E. coli) Contract Manufacturing Introduction
11.11.4 Eurofins Scientific Revenue in GMP Protein (E. coli) Contract Manufacturing Business (2017-2022)
11.11.5 Eurofins Scientific Recent Development
11.12 Arcline Investment Management
11.12.1 Arcline Investment Management Company Detail
11.12.2 Arcline Investment Management Business Overview
11.12.3 Arcline Investment Management GMP Protein (E. coli) Contract Manufacturing Introduction
11.12.4 Arcline Investment Management Revenue in GMP Protein (E. coli) Contract Manufacturing Business (2017-2022)
11.12.5 Arcline Investment Management Recent Development
11.13 Abgenex
11.13.1 Abgenex Company Detail
11.13.2 Abgenex Business Overview
11.13.3 Abgenex GMP Protein (E. coli) Contract Manufacturing Introduction
11.13.4 Abgenex Revenue in GMP Protein (E. coli) Contract Manufacturing Business (2017-2022)
11.13.5 Abgenex Recent Development
11.14 Xpress Biologics
11.14.1 Xpress Biologics Company Detail
11.14.2 Xpress Biologics Business Overview
11.14.3 Xpress Biologics GMP Protein (E. coli) Contract Manufacturing Introduction
11.14.4 Xpress Biologics Revenue in GMP Protein (E. coli) Contract Manufacturing Business (2017-2022)
11.14.5 Xpress Biologics Recent Development
11.15 Avid Bioservices
11.15.1 Avid Bioservices Company Detail
11.15.2 Avid Bioservices Business Overview
11.15.3 Avid Bioservices GMP Protein (E. coli) Contract Manufacturing Introduction
11.15.4 Avid Bioservices Revenue in GMP Protein (E. coli) Contract Manufacturing Business (2017-2022)
11.15.5 Avid Bioservices Recent Development
11.16 Bio-Techne
11.16.1 Bio-Techne Company Detail
11.16.2 Bio-Techne Business Overview
11.16.3 Bio-Techne GMP Protein (E. coli) Contract Manufacturing Introduction
11.16.4 Bio-Techne Revenue in GMP Protein (E. coli) Contract Manufacturing Business (2017-2022)
11.16.5 Bio-Techne Recent Development
11.17 Northway Biotech
11.17.1 Northway Biotech Company Detail
11.17.2 Northway Biotech Business Overview
11.17.3 Northway Biotech GMP Protein (E. coli) Contract Manufacturing Introduction
11.17.4 Northway Biotech Revenue in GMP Protein (E. coli) Contract Manufacturing Business (2017-2022)
11.17.5 Northway Biotech Recent Development
11.18 Aldevron
11.18.1 Aldevron Company Detail
11.18.2 Aldevron Business Overview
11.18.3 Aldevron GMP Protein (E. coli) Contract Manufacturing Introduction
11.18.4 Aldevron Revenue in GMP Protein (E. coli) Contract Manufacturing Business (2017-2022)
11.18.5 Aldevron Recent Development
11.19 Institut M茅rieux
11.19.1 Institut M茅rieux Company Detail
11.19.2 Institut M茅rieux Business Overview
11.19.3 Institut M茅rieux GMP Protein (E. coli) Contract Manufacturing Introduction
11.19.4 Institut M茅rieux Revenue in GMP Protein (E. coli) Contract Manufacturing Business (2017-2022)
11.19.5 Institut M茅rieux Recent Development
11.20 PerkinElmer
11.20.1 PerkinElmer Company Detail
11.20.2 PerkinElmer Business Overview
11.20.3 PerkinElmer GMP Protein (E. coli) Contract Manufacturing Introduction
11.20.4 PerkinElmer Revenue in GMP Protein (E. coli) Contract Manufacturing Business (2017-2022)
11.20.5 PerkinElmer Recent Development
11.21 Creative BioMart
11.21.1 Creative BioMart Company Detail
11.21.2 Creative BioMart Business Overview
11.21.3 Creative BioMart GMP Protein (E. coli) Contract Manufacturing Introduction
11.21.4 Creative BioMart Revenue in GMP Protein (E. coli) Contract Manufacturing Business (2017-2022)
11.21.5 Creative BioMart Recent Development
11.22 Profacgen
11.22.1 Profacgen Company Detail
11.22.2 Profacgen Business Overview
11.22.3 Profacgen GMP Protein (E. coli) Contract Manufacturing Introduction
11.22.4 Profacgen Revenue in GMP Protein (E. coli) Contract Manufacturing Business (2017-2022)
11.22.5 Profacgen Recent Development
11.23 ProBioGen
11.23.1 ProBioGen Company Detail
11.23.2 ProBioGen Business Overview
11.23.3 ProBioGen GMP Protein (E. coli) Contract Manufacturing Introduction
11.23.4 ProBioGen Revenue in GMP Protein (E. coli) Contract Manufacturing Business (2017-2022)
11.23.5 ProBioGen Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Merck
Thermo Fisher Scientific
Abcam
GenScript
Biomay
SOL GROUP
Proteintech Group
Nordmark Pharma
Sino Biological
Abnova Corporation
Eurofins Scientific
Arcline Investment Management
Abgenex
Xpress Biologics
Avid Bioservices
Bio-Techne
Northway Biotech
Aldevron
Institut M茅rieux
PerkinElmer
Creative BioMart
Profacgen
ProBioGen
听
听
*If Applicable.
